By Catherine Eckford (European Pharmaceutical Review)2025-06-02T15:04:19
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-30T14:00:00Z 2026-06-30T15:00:00Z
Sponsored by BioRad
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:30:00Z
Sponsored by bioMérieux
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-05-13T14:00:00 2026-05-13T15:00:00
Sponsored by Thermo Fisher Scientific
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2026-06-30T14:00:00 2026-06-30T15:00:00
Sponsored by BioRad
2025-05-19T09:58:00
Sponsored by bioMérieux, Entegris and Cencora, By European Pharmaceutical Review
Site powered by Webvision Cloud